Get started
Author

Angus C. Jennings

Observed names: Angus C Jennings, Angus Jennings, Jennings, Angus C
ORCID: 0000-0002-4342-4108
Observed ORCID: 0000-0002-4342-4108
OpenAlex ID: A5036937602
Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort
2023 · Abeer Ghuman, Dinesh Khanna, et al. · Rheumatology · 42
PDF
A systematic review of simulation studies which compare existing statistical methods to account for non-compliance in randomised controlled trials
2023 · Lucy Abell, Francesca Maher, et al. · BMC Medical Research Methodology · 10
PDF
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa
2025 · Fredrick Katongole, Tiyara Arumugam, et al. · Contemporary Clinical Trials · 7
Perils of Randomized Controlled Trial Survival Extrapolation Assuming Treatment Effect Waning: Why the Distinction Between Marginal and Conditional Estimates Matters
2023 · Angus C. Jennings, Mark J. Rutherford, et al. · Value in Health · 6
PDF
A Spline‐Based Approach to Smoothly Constrain Hazard Ratios With a View to Apply Treatment Effect Waning
2025 · Angus C. Jennings, Mark J. Rutherford, et al. · Statistics in Medicine · 3
Seeing is believing: Patients’ attitudes and information preferences towards robotic gynaecological surgery
2024 · Ayisha A. Ashmore, Aemn Ismail, et al. · Journal of Gynecology Obstetrics and Human Reproduction · 3
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial
2026 · Adeodata R Kekitiinwa, Angus Jennings, et al. · The Lancet HIV · 2
Trial design and enrolment characteristics of LATA (Long-Acting Treatment in Adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to <20 years, in Sub-Saharan Africa
2026 · Diana Anena, Elizabeth Chappell, et al. · Contemporary Clinical Trials · 2
The Impact of Intradialytic Exercise on the Symptom of CKD Associated Pruritus
2026 · Namrata Joshi, Katherine L. Hull, et al. · Hemodialysis International
PDF
Ethnic reporting and representation in UK COVID-19 consenting observational studies; a systematic review
2026 · Naomi V Bradbury, Sarah Booth, et al. · F1000Research
PDF
A Comparison of F/TAF and F/TDF as HIV Pre-Exposure Prophylaxis in a Predominantly Cisgender Women Population in East and South Africa: A Randomized, Factorial, Noninferiority Trial
2026 · Sheena McCormack, David Dunn, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes
Short-Cycle Therapy (Weekends-Off) on Dolutegravir-Based Antiretroviral Therapy in Adolescents Living with HIV (BREATHER Plus): A Randomised, Open-Label, 96-Week Non-Inferiority Trial
2025 · Adeodata R. Kekitiinwa, Angus Jennings, et al. · SSRN Electronic Journal
Exploring the Skin Symptom Cluster in a Prevalent Hemodialysis (HD) Cohort: The Dominance of CKD-Associated Pruritus and the Association with Fatigue
2023 · Katherine L. Hull, Namrata Joshi, et al. · Journal of the American Society of Nephrology
The Impact of Intradialytic Cycling on the Symptom of CKD-Associated Pruritus
2023 · Namrata Joshi, James Burton, et al. · Journal of the American Society of Nephrology
Works count: 19
Citation count: 75
H-index: 4
I10-index: 2
Year
Topic
Type